Strunk, Daniel
Bauer, Peter
Keyvani, Kathy
Diehl, Rolf R.
Veltkamp, Roland
Berlit, Peter
Meuth, Sven G.
Timmermann, Lars
Schwitalla, Jan Claudius
Kraemer, Markus http://orcid.org/0000-0002-5667-3621
Funding for this research was provided by:
Philipps-Universität Marburg
Article History
Received: 27 December 2023
Revised: 27 January 2024
Accepted: 27 January 2024
First Online: 13 March 2024
Declarations
:
: Daniel Strunk: There is no conflict of interest. Peter Bauer: is chief medical and genomic officer at Centigene AG Rostock. Kathy Keyvani: There is no conflict of interest. Rolf R. Diehl: There is no conflict of interest. Roland Veltkamp: RV is an investigator of the NIHR Imperial Biomedical Research Centre and reports fees for consulting and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Daichi Sankyo, Portola, Biogen, Medtronic, and Morphosys; and research grants from Bayer, Boehringer, Bristol Myers Squibb. Peter Berlit: There is no conflict of interest. Sven G. Meuth: There is no conflict of interest. Lars Timmermann: LT reports grants, personal fees, and non-financial support from SAPIENS Steering Brain Stimulation, Medtronic, Boston Scientific, and St. Jude Medical, and has received payments from Bayer Healthcare, UCB Schwarz Pharma, and Archimedes Pharma and also honoraria as a speaker on symposia sponsored by Teva Pharma, Lundbeck Pharma, Bracco, Gianni PR, Medas Pharma, UCB Schwarz Pharma, Desitin Pharma, Boehringer Ingelheim, GSK, Eumecom, Orion Pharma, Medtronic, Boston Scientific, Cephalon, Abbott, GE Medical, Archimedes, and Bayer. Jan Claudius Schwitalla: JCS is a full-time employee of Astra Zenica, but this article was written as part of his voluntary work on the board of the German Moyamoya Association. Markus Kraemer: MK received honoraria for lecture activities from Roche Pharma and Chugai without any connection to the topic of the article.